疏风解毒胶囊在慢性阻塞性肺疾病急性加重期伴肺部感染治疗中的应用研究

Application of Shufeng Jiedu Capsule in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Pulmonary Infection

目的探究疏风解毒胶囊在慢性阻塞性肺疾病(COPD)急性加重期伴肺部感染治疗中的应用研究。方法选取2015年1月—2018年1月该院收治的COPD急性加重期伴肺部感染患者226例,随机分为对照组(n=113)和观察组(n=113)。对照组给予单纯西医对症治疗,观察组在对照组基础上给予疏风解毒胶囊治疗,两者患者均治疗10 d。统计两组治疗后临床疗效、生活质量评分、不良反应发生率(包括睡眠呼吸障碍、继发性红细胞增多症、慢性肺源性心脏病、自发性气胸以及总的不良反应发生率),治疗前后两组患者的临床CPIS评分和血清炎症标记物,包括hs-CRP、PCT。结果治疗后,观察组、对照组总有效率分别为88.50%(100/113)、70.80%(80/113),观察组显著高于对照组(P <0.01);与治疗前比较,治疗后观察组hs-CRP、PCT和CRIS评分均降低,且观察组显著低于对照组(P <0.01);治疗后观察组ADL评分显著高于对照组(P <0.01);治疗期间,观察组、对照组患者不良反应发生率分别为8.85%(10/113)、19.47%(22/113),观察组显著低于对照组(P <0.05)。结论在西医常规治疗的基础上加用疏风解毒胶囊治疗COPD急性加重期伴肺部感染能够有效改善患者临床症状,控制感染,减轻炎性反应,且不良反应小、安全有效,有利于临床推广。

Objective To explore the application of Shufeng Jiedu Capsule in the treatment of acute exacerbation of COPD with pulmonary infection. Methods A total of 226 patients with acute exacerbation of COPD accompanied by pulmonary infection in our hospital from January 2015 to January 2018 were randomly divided into control group( n = 113) and observation group( n = 113).The control group was given symptomatic treatment by western medicine alone,while the observation group was given Shufeng Jiedu Capsule on the basis of the control group. Both patients were treated for 10 days. The clinical efficacy,quality of life score and adverse reactions( including sleep apnea disorder,secondary polycythemia,chronic pulmonary heart disease,spontaneous pneumothorax and total incidence of adverse reactions) were analyzed. The clinical CPIS score and serum inflammatory markers,including hs-CRP and PCT,were recorded before and after treatment. Results After treatment,the total effective rates of the observation group and the control group were 88. 50%( 100/113) and 70. 80%( 80/113),respectively. The observation group’s rate was significantly higher than that of the control group( P < 0. 01). Compared with those before treatment,the scores of hs-CRP,PCT and CRIS in the observation group were lower after treatment,and the scores in the observation group were significantly lower than those in the control group( P < 0. 01). After treatment,ADL score in the observation group was significantly higher than that in the control group( P < 0. 01). The total incidence of adverse reactions in the observation group and the control group were8. 85%( 10/113) and 19. 47%( 22/113),respectively. The incidence of adverse reactions in the observation group was significantly lower than that in the control group( P < 0. 05). Conclusion On the basis of routine treatment of Western medicine,Shufeng Jiedu Capsule can effectively improve the clinical symptoms,control infection and alleviate inflammatory reaction of patients with acute exacerbation of COPD accompanied by pulmonary infection. The adverse reactions are few. It is safe and effective,which is conducive to clinical promotion.